Phase 2 Eating Disorders Trial, Recruiting NCT07169747 Sponsor: Region Skane Condition: Eating Disorders
Back to Eating Disorders

Phase 2 Eating Disorders Trial, Recruiting

NCT07169747
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with anorexia nervosa (AN) according to standard diagnostic guidelines (DSM-5)
  • You have had at least one period of recovery (reaching a BMI of 17 or above) followed by a return of the illness
  • You are between 16 and 35 years old
  • Your current BMI is above 16
  • You are regularly in contact with a psychiatric care team
  • You are able to understand and agree to take part in the study (give informed consent)

Who may not be able to join:

  • You have been diagnosed with psychosis, bipolar disorder, or a substance use disorder, or have a family history of psychosis or bipolar disorder
  • You are unwilling to use birth control during the study
  • You have ever used psychedelic substances
  • You are currently taking certain medications that cannot be safely stopped or paused before the study (confirm with trial site)
  • You have a heart or cardiovascular condition
  • Your blood pressure is too high at the time of screening (above 140/90 mmHg)
  • You have a significant irregular heartbeat or a specific heart rhythm abnormality (confirm with trial site)
  • You have a history of stroke, heart attack, or other major heart-related events
  • You have epilepsy or a seizure disorder
  • You have diabetes, test positive for certain drugs, have active suicidal thoughts, have an allergy to the study drug, or have a fear of blood or needles
  • For the brain scan (MRI) part of the study only: you have metal implants or objects in your body — though declining the MRI scan will not remove you from the rest of the study
  • You have any other significant medical condition that the study doctor believes could put you at risk or affect the study results
  • You are currently receiving compulsory psychiatric care under Swedish law (LPT)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pouya Movahed Rad, Associate Professor, Department of Clinical Sciences, Lund University, Sweden

Phone: +46739075390

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Region Skane
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
1 October 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

To assess the safety and tolerability of psilocybin 25 mg in young adults with anorexia nervosa, as measured by incidence of adverse events (AEs) and serious adverse events (SAEs).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov